Wall Street Bullish on ​Precigen (PGEN) As the Company Transitions to Commercial Stage

​Precigen, Inc. (NASDAQ:PGEN) is one of the Best Rising Penny Stocks to Buy Now.

​Wall Street is bullish on Precigen, Inc. (NASDAQ:PGEN) after the company posted encouraging fiscal Q4 2025 earnings on March 25. Following the release on April 2, H.C. Wainwright reiterated a Buy rating on the stock with a $10 price target. Earlier on March 26, Citizen JMP had raised the price target on the stock from $8 to $9, while reiterating a Buy rating on the shares.

​Precigen, Inc. (NASDAQ:PGEN) transitioned from a clinical to commercial stage company in August 2025 with the FDA approval for PAPZIMEOS to treat adults with recurrent respiratory papillomatosis (RRP). During the fiscal fourth quarter of 2025, PAPZIMEOS generated $3.4 million in net sales and marked the first partial quarter of US commercial sales.

​Management noted that the Centers for Medicare & Medicaid Services has assigned a J-code J3404 to the therapy effective April 1, 2026. As a result, the company expects fiscal Q1 2026 revenue for the drug to exceed $18 million.

​Precigen, Inc. (NASDAQ:PGEN) is a biopharmaceutical company focused on developing next-generation gene and cell therapies, specifically in immuno-oncology, autoimmune disorders, and infectious diseases.

While we acknowledge the risk and potential of PGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PGEN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Hot Growth Stocks to Invest in Right Now and 7 Ridiculously Cheap Stocks to Buy According to Wall Street Analysts. 

Disclosure: None. Follow Insider Monkey on Google News.